
Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Idera Pharmaceuticals, Inc."
Count: 15
Selected: 0
NCT ID | Title |
---|
NCT03445533 | A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma | ||
NCT02644967 | A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma | ||
NCT01899729 | A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis | ||
NCT03865082 | Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | ||
NCT03052205 | A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors | ||
NCT02612857 | Trial of IMO-8400 in Adult Patients With Dermatomyositis | ||
NCT02092909 | Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia | ||
NCT00990938 | Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients | ||
NCT00728936 | Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients | ||
NCT00729053 | Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma | ||
NCT02363439 | Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401 | ||
NCT01622348 | Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis | ||
NCT02252146 | Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation | ||
NCT04196283 | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | ||
NCT04126876 | A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma |